Premium
Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma
Author(s) -
Chang Hong,
Ning Yi,
Qi Xiaoying,
Yeung Joanna,
Xu Wei
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06750.x
Subject(s) - multiple myeloma , fluorescence in situ hybridization , chromosome , biology , medicine , overall survival , multivariate analysis , pathology , gene , genetics
Summary The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression‐free survival (PFS) (median 10·5 vs. 22·3 months, P = 0·0002) and shorter overall survival (OS) (median 33·9 months vs. not reached, P = 0·002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53 , t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS ( P = 0·01) and OS ( P = 0·04).